is retatrutide a triple agonist Reta clinical trial data & dosing — must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP retatrutide triple agonist glp-1 gip

In a Phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023), adults with obesity (without type 2 diabetes) who received the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks

doi: 10.1111/bcp.13636 28 von ElmEAltmanDGEggerMPocockSJGotzschePCVandenbrouckeJPet al

Not everyone taking GLP-1 medications experiences hair loss

Window Weeks 2-3 What's commonly tracked Resting weight, waist circumference, fasting glucose trend What it tells you Identifies early water retention or unusual abdominal expansion

the smell is harmless and often diminishes when dosing is slowed or reduced

Old drugs